Exosome biomarkers for prediction and diagnosis of Parkinson’s Disease

Applications: Diagnostic, Biomarkers, Screening, Parkinson’s Disease

Isolation of neuronal exosomes from blood allows for prediction of individuals who are likely to progress to PD, and differentiate those with PD from Parkinson’s-like diseases. Suitable for clinical trial recruitment.

Features	Benefits
Identification of the neuronal exosomes that contain clinically relevant information	Targeted exosome analysis removes confusion seen in many studies of α-synuclein as a biomarker
Two biomarkers that can be measured associated with PD – α-synuclein and Clusterin	Greater than 90% sensitivity and specificity in differentiation of PD, even in the prodromal phase
Biomarkers validated on large international cohorts	Strong evidence supporting the use of these biomarkers amongst three PD cohorts
Differentiate healthy controls from individuals with PD or will develop PD, and those with PD-like disease, tauopathies, non-α-synuclein proteinopathies	Diagnostic applications Predictive applications Screening applications Suitable for clinical trial recruitment
Run using blood-based samples – whole blood, serum, plasma	Allows for rapid high throughput analysis and patient screening

Request more information
about this technology

Back to Technologies Available

Technologies for License

Exosome biomarkers for prediction and diagnosis of Parkinson’s Disease

Ready to get in touch?